Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2008

Vermillion Inks Exclusive License for Stanford University’s PAD Biomarker Panel

  • Stanford University granted Vermillion exclusive rights to the biomarker panel related to peripheral artery disease (PAD). Stanford and Vermillion have already completed a 540-patient clinical study evaluating the ability of the biomarker panel to classify individuals into high and low risk groups for PAD.

    Based on these results, the company plans to further develop the panel for risk assessment. Vermillion will commercialize a blood test utilizing the multimarker panel to stratify an individual’s danger for developing the disease.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »